Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04098211 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency Patients

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 2024 to Dec 2026v8
  2. Primary and study completion dates: Dec 2023 to Dec 2024v7
  3. Primary and study completion dates: Dec 2022 to Dec 2023v6
  4. Primary completion date: Jul 2022 to Dec 2022v5
  5. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Site contact updatedv3
  2. Start date changed from estimate of Sep 23, 2019 to Nov 1, 2019v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to gather information on the possible symptoms that patients with atypical neuronal ceroid lipofuscinosis type 2 (also known as aTPP1 or atypical tripeptidyl peptidase deficiency) have and how they change over time.
Trial Details
NCT Number NCT04098211
Lead Sponsor Children's Hospital of Orange County
Conditions
(from sponsor)		 Neuronal Ceroid-Lipofuscinoses, Neuronal Ceroid Lipofuscinosis CLN2, Spinocerebellar Ataxia, Autosomal Recessive 7
Related terms Neuronal Ceroid-Lipofuscinoses, Spinocerebellar Ataxia, Autosomal Recessive 7
Enrollment 5 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov